Zoetis
Zoetis Inc. is the world’s largest animal health company, established in 2013 as a spin-off from Pfizer’s animal health division, and is a dominant force in the veterinary biologics market. The company operates globally, providing a comprehensive portfolio of medicines, vaccines, and diagnostic products for both companion animals and livestock across approximately 120 countries. Zoetis’s leadership is built on continuous innovation, particularly in the biologics segment, where its products—including vaccines, immunotherapies, and monoclonal antibodies—address critical areas like pain management, dermatology, and infectious disease prevention. The company has successfully introduced ground-breaking biologic treatments, such as Librela (bedinvetmab injection) for canine osteoarthritis pain, an innovative monoclonal antibody therapy. Zoetis is consistently focused on expanding its manufacturing capabilities for vaccines and biologics globally, exemplified by its acquisition of a new manufacturing facility in Australia in 2024 to amplify its vaccine development capacity for diverse species. Through its extensive R&D and strategic investments in advanced digital platforms and machine learning, Zoetis remains at the forefront of the veterinary biologics industry, driving growth and ensuring the health and productivity of animals worldwide.
Latest Market Research Report on Veterinary Biologics Download PDF Brochure Now
Boehringer Ingelheim Animal Health
Boehringer Ingelheim Animal Health, a division of the German-based multinational pharmaceutical company, is one of the top three global animal health firms and a pivotal player in the veterinary biologics market. The company’s foundation dates back to 1885, and its animal health portfolio is renowned for providing some of the most highly regarded and broadly used vaccines and parasite-control products for both pets and livestock. As a research-driven organization, Boehringer Ingelheim dedicates significant resources to the discovery, development, and manufacturing of innovative health care products. In the biologics space, they offer an extensive line of vaccines, such as Ingelvac CircoFLEX for swine and the comprehensive Nobivac line for pets, which are essential for large-scale disease prevention and public health protection. Furthermore, their expertise in biopharmaceutical contract manufacturing also supports advanced therapeutic strategies. Their integrated approach to animal health, which spans from innovative product development to global distribution, solidifies Boehringer Ingelheim’s position as a key global partner in advancing preventive and therapeutic solutions in the veterinary biologics industry.
Merck Animal Health (MSD Animal Health)
Merck Animal Health, known as MSD Animal Health outside the US and Canada, is a prominent global player in the veterinary biologics market, backed by its parent company Merck & Co., Inc.’s long legacy of scientific excellence since 1891. The division is dedicated to preserving and improving the health, well-being, and performance of animals by providing a wide range of veterinary pharmaceuticals, vaccines, and biologics for companion animals and livestock. Merck prioritizes the development of advanced biologics, demonstrated by its strong pipeline and significant R&D investments, including an $895 million expansion of its manufacturing and R&D facilities in De Soto, Kansas, focused on biologics and vaccine development, including monoclonal antibody therapies. Their extensive product line includes major vaccine brands like Nobivac and Porcilis and their innovative biologics are constantly being expanded. For instance, the company actively seeks to increase production capacity for its vaccines and has recently acquired the aqua business segment of Elanco, expanding its cold and warm water aqua products across vaccines and anti-parasitic treatments. Merck Animal Health’s commitment to the One Health approach and its global network of research and manufacturing facilities reinforce its role as a leader in delivering effective, high-quality veterinary biologics.
Elanco Animal Health
Elanco Animal Health is a global leader committed to enhancing animal health and food supply sustainability through a robust portfolio of animal medicines, feed additives, and diagnostic products. Established as a leading player in the veterinary biologics market, Elanco provides solutions for a wide array of species, including dogs, cats, cattle, poultry, and swine. A significant part of Elanco’s strategy in biologics involves developing and commercializing advanced therapies, especially in the realm of monoclonal antibodies (mAbs). The company has made headlines with the introduction of innovative mAb treatments, such as the world’s first USDA conditionally approved mAb treatment for canine parvovirus, alongside continuous investment in R&D and expanded biologics manufacturing capabilities. This focus on cutting-edge biologics addresses critical needs in both pet health and farm animal care. Through strategic acquisitions and a strong global presence in over 90 countries, Elanco is continuously strengthening its market coverage and product offerings, providing essential, reliable, and sustainable solutions that prevent and treat diseases, thereby making it a key force driving the future of veterinary biologics.
Ceva Santé Animale
Ceva Santé Animale (Ceva) is a prominent, research-driven French multinational veterinary pharmaceutical company and a top-tier player in the animal health market, with a strong focus on veterinary biologics, particularly vaccines. The company is committed to delivering preventive care products and solutions that address major contemporary challenges, notably antimicrobial resistance and emerging zoonoses. Ceva’s strength in biologics is underpinned by its investment in its global network and active R&D programs, resulting in a broad and innovative vaccine portfolio, including products like Vectormune ND for poultry against Newcastle disease. Ceva actively expands its biotechnology capabilities through strategic acquisitions, such as the purchase of Scout Bio in 2024 to enhance its pet therapeutics and biotechnology innovation, with a focus on advanced treatments for chronic diseases. By combining its expertise in pharmaceuticals and biologics, Ceva provides a comprehensive suite of products that serve both companion and commercial animal sectors globally. Its dedication to responsible animal care and the development of solutions for infectious disease prevention validates its important position in the veterinary biologics market.
Virbac
Virbac S.A. is a prominent French animal health company with a comprehensive and extensive product portfolio that includes a strong line of veterinary biologics, parasiticides, and nutritional supplements. Established with a focus on the needs of veterinarians and animal owners, the company delivers innovative solutions for diagnosing, preventing, and treating a wide range of animal health disorders across more than 100 countries. In the biologics sector, Virbac offers key preventive products like the CaniLeish vaccine for canine leishmaniasis and various other vaccines. The company is known for its dedication to developing affordable veterinary solutions, often expanding its offerings in emerging markets. Virbac’s strength lies in its agility and regional customization, which allows it to efficiently adapt its diagnostic and preventive applications to evolving consumer and veterinarian demands. By continually focusing on sustainability and a broad spectrum of products, from vaccines to nutritional health, Virbac solidifies its role as a significant and innovative player in the global veterinary biologics and general animal health market.
IDEXX Laboratories, Inc.
IDEXX Laboratories, Inc. is a global leader primarily known for its innovative veterinary diagnostics and information management systems, which makes it a crucial indirect player in the veterinary biologics ecosystem. While not a primary vaccine manufacturer, IDEXX’s proprietary technologies are essential for the effective use and monitoring of biologics, such as vaccines and monoclonal antibodies. Their diagnostic kits and instruments empower veterinarians with rapid and accurate testing, which is fundamental for confirming the need for a biologic product (e.g., infectious disease status), monitoring an animal’s response to a therapeutic biologic, and ensuring overall health management. By focusing on digital workflow solutions and information management, IDEXX enables veterinarians to practice personalized and connected animal care, maximizing the clinical outcomes of all treatments, including biologics. The company’s critical role in providing the “intelligence” layer—the ability to accurately diagnose and monitor disease—makes it a key and prominent enabling player in the veterinary biologics market, particularly in small animal clinics worldwide.
Phibro Animal Health Corporation
Phibro Animal Health Corporation is a global animal health and mineral nutrition company that maintains a presence in the veterinary biologics market, primarily through its focus on products for food and companion animals. The company develops, manufactures, and markets a broad range of products, including vaccines and performance-enhancing nutritional supplements for species such as poultry, swine, beef and dairy cattle, and aquaculture. While heavily focused on medicated feed additives and nutritional products—a segment it significantly expanded by acquiring Zoetis’s feed additive portfolio—Phibro also plays a role in disease prevention. Their biologics efforts align with their mission to enhance livestock productivity and food quality globally. By actively operating in over 80 countries, Phibro’s broad North American and international base allows it to influence global animal health practices. The company’s strategy involves integrating nutrition, disease prevention, and therapeutic support to ensure overall animal well-being, cementing its position as a diversified contributor to the broader veterinary biologics and health market.
Vetoquinol
Vetoquinol S.A. is an independent French company specializing in veterinary pharmaceuticals and is a prominent player with a presence in the biologics-related market, serving both companion animals and livestock globally. The company commercializes products across key therapeutic areas, including anti-infectives, pain, inflammation, and cardiology, and has a strategic focus on generics and specialty medicines. Vetoquinol’s product portfolio includes various items for biosecurity and preventive care. For example, products like Felpreva and Marbocyl demonstrate their commitment to comprehensive animal health. While primarily a pharmaceutical company, Vetoquinol’s strategic adaptability and broad portfolio mean it interacts significantly with the biologics space, often providing supporting products for conditions that are also addressed by biologics. By ensuring competitive pricing and broad market reach across both developed and price-sensitive regions, Vetoquinol plays a crucial role in providing accessible healthcare solutions, including preventative and therapeutic options that complement the high-growth biologics segment of the animal health market.
HIPRA
HIPRA is a Spanish-based multinational pharmaceutical company dedicated to animal health, distinguished by its strong focus on prevention through an innovative line of veterinary biologics, particularly vaccines. The company is actively involved in the research, development, production, and commercialization of a wide range of advanced vaccines, primarily for livestock, including swine and bovine species. HIPRA’s commitment to enhancing food safety is driven by its advanced livestock immunization programs. Their proprietary products, such as Hiprasuin (swine reproductive vaccine) and Hiprabovis (bovine respiratory vaccine), highlight their specialization in developing highly effective preventive solutions for diseases that impact major food animal production sectors. With a robust R&D footprint and significant market presence in Europe and Latin America, HIPRA differentiates itself by offering unique, high-value vaccines tailored to regional disease challenges. The company’s focus on the entire value chain—from R&D to manufacturing and technical support—reinforces its identity as a key, specialized global player, driving technological advancements in the field of veterinary biologics and contributing significantly to the global food industry’s sustainability and health.
Latest Market Research Report on Veterinary Biologics Download PDF Brochure Now